uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Trading 06-18 13:38:36 EDT

46.59

-1.57

-3.25%

High50.08	Low46.07	Vol2.23M
Open48.88	D1 Closing48.16	Amplitude8.33%
Mkt Cap2.94B	Tradable Cap2.32B	Total Shares63.03M
T/O105.93M	T/O Rate4.49%	Tradable Shares49.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":46.5925,"timestamp":1781804310034,"preClose":48.16,"halted":0,"volume":2233564,"delay":0,"changeRate":-0.03254775747508296,"floatShares":49724600,"shares":63033249,"eps":-3.486371,"marketStatus":"Trading","change":-1.5675,"latestTime":"06-18 13:38:36 EDT","open":48.875,"high":50.08,"low":46.07,"amount":105930927.12903999,"amplitude":0.083264,"askPrice":46.64,"askSize":100,"bidPrice":46.54,"bidSize":106,"shortable":3,"etf":0,"ttmEps":-3.486371,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781812800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":48.16,"preHourTrading":{"tag":"盘前","latestPrice":49.15,"preClose":48.16,"latestTime":"09:29 EDT","volume":69685,"amount":3403501.53066,"timestamp":1781789399999,"change":0.99,"changeRate":0.020556,"amplitude":0.050386},"postHourTrading":{"tag":"盘后","latestPrice":48.09,"preClose":48.16,"latestTime":"19:59 EDT","volume":129101,"amount":6216373.2637,"timestamp":1781740759501,"change":-0.07,"changeRate":-0.001453,"amplitude":0.019956},"volumeRatio":0.742358,"optionData":{"bulkOrders":[{"symbol":"QURE","call":true,"expireDate":1799989200000,"strike":"90.0","timestamp":1781793100324,"price":5.8,"volume":6000,"amount":3480000,"type":"-"},{"symbol":"QURE","call":true,"expireDate":1799989200000,"strike":"50.0","timestamp":1781793100324,"price":14.4,"volume":3000,"amount":4320000,"type":"+"}]},"impliedVol":1.1276,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2644087227","title":"uniQure Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2644087227","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644087227?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:06","pubTimestamp":1781798760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 18, 2026 12:06 ET (16:06 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644708783","title":"UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644708783","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644708783?lang=en_us&edition=fundamental","pubTime":"2026-06-18 23:37","pubTimestamp":1781797030,"startTime":"0","endTime":"0","summary":"UniQure  has a clearer path toward possible accelerated approval of its investigational drug for Huntington's disease after the US Food and Drug Administration signaled it is open to accepting a biologics license application based on three-year data, RBC Capital Markets said in a note Wednesday.The investment firm said the regulator will likely accept a BLA with priority review when the company files it in Q3 because of the unmet need.The FDA's willingness to consider the filing without waiting for four-year data and placebo-controlled trial signals regulatory leniency that is also \"great news\" for the broader industry and improves the outlook for the drug, according to the note.Analysts said they now estimate a 75% chance of approval, compared with 50% previously, although the company still needs to reach alignment with the FDA on the confirmatory trial details prior to BLA submission.RBC has an outperform, speculative risk rating on the stock, with a price target raised to $65 from $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0708994859.HKD","LU0109394709.USD","LABU","LU1267930573.SGD","LU0128525929.USD","LU0889565916.HKD","BK4207","BK4139","LU0320765992.SGD","BK4585","QURE","LU0029864427.USD","BK4588","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808841","title":"uniQure price target raised to $70 from $36 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808841","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808841?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:31","pubTimestamp":1781782263,"startTime":"0","endTime":"0","summary":"Leerink raised the firm’s price target on uniQure (QURE) to $70 from $36 and keeps an Outperform rating on the shares. The firm caught up with uniQ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-raised-to-70-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-raised-to-70-from-36-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644088464","title":"Analysts Are Bullish on These Healthcare Stocks: uniQure (QURE), Biohaven Ltd. (BHVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644088464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644088464?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:30","pubTimestamp":1781782212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE), Biohaven Ltd. (BHVN) and Align Tech ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-uniqure-qure-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-uniqure-qure-biohaven-ltd-bhvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","QURE","BHVN","LU1093756325.SGD","BK4139","LU0889565916.HKD","LU0320765992.SGD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644700705","title":"uniQure upgraded to Overweight from Equal Weight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2644700705","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644700705?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:12","pubTimestamp":1781781152,"startTime":"0","endTime":"0","summary":"Barclays upgraded uniQure (QURE) to Overweight from Equal Weight with a $65 price target Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-upgraded-to-overweight-from-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-upgraded-to-overweight-from-equal-weight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","QURE","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644700337","title":"RBC Raises Price Target on uniQure to $65 From $35, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644700337","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644700337?lang=en_us&edition=fundamental","pubTime":"2026-06-18 19:00","pubTimestamp":1781780439,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has an average rating of buy and mean price target of $56.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644707531","title":"Uniqure Nv : Leerink Partners Raises Target Price to $70 From $36","url":"https://stock-news.laohu8.com/highlight/detail?id=2644707531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644707531?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:41","pubTimestamp":1781779270,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q0MF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","QURE","LU0109394709.USD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644691770","title":"TD Cowen Sticks to Their Buy Rating for uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644691770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644691770?lang=en_us&edition=fundamental","pubTime":"2026-06-18 14:55","pubTimestamp":1781765749,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Joseph Thome from TD Cowen maintained a Buy rating on uniQure. The company’s shares closed yesterday at $48.16. Acc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-sticks-to-their-buy-rating-for-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","TD","COWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644724602","title":"uniQure director Madhavan Balachandran disposes of USD 278,500 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644724602","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644724602?lang=en_us&edition=fundamental","pubTime":"2026-06-18 05:02","pubTimestamp":1781730174,"startTime":"0","endTime":"0","summary":"uniQure director Balachandran Madhavan sold 10,000 ordinary shares on June 15, 2026 at a weighted average price of USD 27.85.The sale followed the exercise of stock options for 10,000 shares at USD 8.49 on the same day.Madhavan ended the day with 43,254 ordinary shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. uniQure NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLtl6Bj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"uniQure director Madhavan Balachandran disposes of USD 278,500 in common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4139","LU0320765992.SGD","QURE","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644045721","title":"Under the Radar: uniQure Shares Surge After FDA's Reversal on Gene Therapy -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2644045721","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644045721?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:48","pubTimestamp":1781729280,"startTime":"0","endTime":"0","summary":"Shares of biotech uniQure jumped 78% on Wednesday after it said the Food and Drug Administration had reversed itself and agreed to accept data from the company's early-stage trial to support an approval filing for its gene therapy for a rare inherited condition called Huntington's disease.The FDA first gave Amsterdam-based uniQure the go-ahead to submit its application for approval without running a Phase 3 trial-which is what is typically needed for such a submission-in 2024. The agency reversed course in 2025, citing the same data it had once accepted. By early 2026, it was pushing uniQure toward a new, yearslong trial that would randomly assign patients to the real therapy or a placebo before allowing any filing. Wednesday's reversal, which comes just over a month after the departure of Marty Makary as FDA Commissioner, allows the company to file without that trial.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","LU0889565916.HKD","LABU","LU0109394709.USD","LU0320765992.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644723557","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644723557","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644723557?lang=en_us&edition=fundamental","pubTime":"2026-06-18 01:40","pubTimestamp":1781718018,"startTime":"0","endTime":"0","summary":"AstroNova  signed an agreement to be acquired by Arcline Investment Management for $29 per share in an all-cash deal with an enterprise value of about $272 million, it said Wednesday.Shares surged 70% as intraday trading volume jumped to over 1.77 million from a daily average of about 56,000.uniQure's  shares soared 75% amid heavy trading after the company said Wednesday it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Intraday trading volume climbed to more than 13.8 million from a daily average of roughly 1.75 million.La-Z-Boy's  reported overnight a year-over-year gain in fiscal Q4 earnings and said it expects sales to outperform the industry in the ongoing quarter.Shares jumped past 19% following an increase in intraday trading volume to over 1.77 million from a daily average of about 413,000.Price: 28.35, Change: +11.66, Percent Change: +69.88","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4095","QURE","BK4516","LU0109394709.USD","LU0320765992.SGD","ALOT","LU0889565916.HKD","LZB","BK4170","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644740581","title":"uniQure upgraded to Overweight from Neutral at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2644740581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644740581?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:45","pubTimestamp":1781711156,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska upgraded uniQure (QURE) to Overweight from Neutral. Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-upgraded-to-overweight-from-neutral-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644751747","title":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron","url":"https://stock-news.laohu8.com/highlight/detail?id=2644751747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644751747?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:42","pubTimestamp":1781710974,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, MicronWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL6N42P12K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEO","WNC","LZB","SNBR","INTW","LDOS","CME","KLAC","VSTM","SVAQ","WBX","KMX","TGE","LINT","QURE","SOPH","BWXT","HOOI","ICCM","KLAG","SATG","ADTX","EHGO","TXG","MU","HOOY","SATS","ASTS","JBL","INLF","ADPT","MUU","FTHM","LRCU","GNK","HOOX","HOOD","BIRD","CVNX","ASTN","SKIL","ASTX","SHAZ","PTRN","INTC","AMAT","WDC","LRCX","DSX","CVNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742749","title":"UniQure Stock (QURE) Rockets on an FDA Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742749","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644742749?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:56","pubTimestamp":1781708164,"startTime":"0","endTime":"0","summary":"UniQure stock was up on Wednesday after the company announced an updated from the FDA.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/uniqure-stock-qure-rockets-on-an-fda-update?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/uniqure-stock-qure-rockets-on-an-fda-update?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LABU","LU0889565916.HKD","LU0320765992.SGD","BK4139","BK4585","QURE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644573744","title":"This Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2644573744","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644573744?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:10","pubTimestamp":1781705400,"startTime":"0","endTime":"0","summary":"Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened.Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market.The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines.The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their applicatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","LU0320765992.SGD","LU0109394709.USD","QURE","BK4588","BK4139","LABU","BK4585","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644741508","title":"Uniqure Nv : Van Lanschot Kempen Raises Target Price to $60 From $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2644741508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644741508?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:40","pubTimestamp":1781703617,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","QURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749742","title":"uniQure AMT-130 update ‘materially positive,’ says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749742","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644749742?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:15","pubTimestamp":1781702138,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating on uniQure (QURE) after the company announced that, during a recent Type B meeting...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-amt-130-update-materially-positive-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-amt-130-update-materially-positive-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0320765992.SGD","BK4084","LU0109394709.USD","AMT","BK4588","QURE","BK4554","BK4139","BK4585","LU0889565916.HKD","BK4534","BK4219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644272743","title":"UniQure to Seek FDA Approval to Market Huntington's Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2644272743","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644272743?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:41","pubTimestamp":1781696460,"startTime":"0","endTime":"0","summary":"UniQure said it plans to apply for regulatory approval to market one of its primary investigational gene therapies as a treatment for Huntington's disease.During a recent meeting with the Food and Drug Administration, the agency told the company that a three-year analysis from a study of UniQure's AMT-130 drug would be acceptable as the primary basis for a Biologics License Application to accelerate approval of the drug in Huntington's disease, UniQure said.The FDA is also seeking to align on the design of a confirmatiory study prior to the submission of the application, the company said.UniQure said it is committed to conducting the confirmatory study without delay and expects to align with the FDA on the details. It aims to submit the application in the third quarter of this year.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","QURE","LABU","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644585743","title":"uniQure announces plan for BLA submission for AMT-130","url":"https://stock-news.laohu8.com/highlight/detail?id=2644585743","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644585743?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:10","pubTimestamp":1781694612,"startTime":"0","endTime":"0","summary":"uniQure (QURE) announced that, during a recent Type B meeting with the FDA, the FDA communicated that the three-year analysis from the Phase I/II s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-announces-plan-for-bla-submission-for-amt-130-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-announces-plan-for-bla-submission-for-amt-130-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4534","BK4139","BK4581","BK4554","LABU","BK4588","QURE","LU0320765992.SGD","AMT","LU0109394709.USD","BK4219","BK4084","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644482227","title":"uniQure says FDA accepts Phase I/II data as basis for AMT-130 accelerated approval BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2644482227","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644482227?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:05","pubTimestamp":1781694320,"startTime":"0","endTime":"0","summary":"uniQure plans to submit a BLA in Q3 2026 seeking FDA accelerated approval for AMT-130 in Huntington’s disease.FDA indicated the Phase I/II 3-year analysis could support the filing as the primary basis for review.Agency wants alignment on the confirmatory study design before submission, including a concurrent standard-of-care control instead of a sham procedure.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL10hJX1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","LU0314104364.USD","QURE","LU0889565916.HKD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","SG9999014039.USD","BK4139","SG9999014005.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0109394709.USD","IE00BGHQF748.EUR","LU0320765992.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","BK4112","NDAQ","SG9999014021.USD","BK4585","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.7957},{"period":"1month","weight":0.9318},{"period":"3month","weight":2.156},{"period":"6month","weight":1.0075},{"period":"1year","weight":2.2563},{"period":"ytd","weight":1.0125}],"compareEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.123},{"period":"6month","weight":0.0887},{"period":"1year","weight":0.24},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.307692,"avgChangeRate":-0.046417},{"month":4,"riseRate":0.461538,"avgChangeRate":0.033828},{"month":5,"riseRate":0.692308,"avgChangeRate":0.072742},{"month":6,"riseRate":0.461538,"avgChangeRate":0.044216},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}